美國Illumina www.illumina.com.cn  www.illumina.com
Illumina公司 (www.illumina.com)是全球領(lǐng)先的新一代生命科學工具的開發(fā)和生產(chǎn)者，并開發(fā)大規(guī)模分析遺傳變異和生物功能的集成工具。我們利用專利技術(shù)，為測序、基因分型和基因表達提供全面的產(chǎn)品和服務(wù)，還將進入分子診斷市場。我們的客戶包含一流的基因研究中心、藥廠、研究院、臨床研究機構(gòu)和生物公司。我們的工具有足夠的表現(xiàn)力、通量、成本效益和靈活性，使全世界的研究者能通過遺傳實驗來得到有價值的信息。我們相信這個信息能使研究者把遺傳變異與生物功能關(guān)聯(lián)起來，從而加大藥物開發(fā)和臨床研究，讓疾病能更早地檢測出來，為患者提供更好的藥物。
Illumina的目標是用創(chuàng)新的技術(shù)以及革命性的檢測手段提供基因變異 和功能研究， 這些研究使得個人化醫(yī)療成為可能。作為一家全球性公司，Illumina 以嶄新的技術(shù) 在創(chuàng)新性，靈活性，可升級性，以及一流的服務(wù)與支持等方面創(chuàng)新了新的業(yè)界標準。illumina于1998年4月創(chuàng)立，2000年7月于Nasdaq上市，總部設(shè)在加利福尼亞的圣迭戈。
Illumina創(chuàng)新的芯片技術(shù)被稱之為微珠芯片技術(shù)（BeadArray），在這項技術(shù)的幫助下，Illumina 擊敗了眾多競爭對手，成為人類基因組項目最主要的基因芯片供應(yīng)商，在2001年開始的“國際單體型測繪計劃”（International HapMap Project）中提供SNP分型檢測芯片，這個項目由六個國家發(fā)起，擁有 1 億美元的后續(xù)研發(fā)資金，其宗旨是探索人的獨特性，尋找個體對疾病的敏感性，以及對藥物的不同反應(yīng)的根本原因。
這項專利的技術(shù)目前已經(jīng)擴展應(yīng)用到DNA， RNA和蛋白質(zhì)研究，對于疾病研究、藥物 研發(fā)和分子診斷等領(lǐng)域。
是新一代生命科學工具的領(lǐng)先開發(fā)和生產(chǎn)者，并開發(fā)大規(guī)模分析遺傳變異和生物功能的集成工具。我們利用專利技術(shù)，為測序、基因分型和基因表達提供全面的產(chǎn)品和服務(wù)，還將進入分子診斷市場。我們的客戶包含一流的基因研究中心、藥廠、研究院、臨床研究機構(gòu)和生物公司。我們的工具有足夠的表現(xiàn)力、通量、成本效益和靈活性，使全世界的研究者能通過遺傳實驗來得到有價值的信息。我們相信這個信息能使研究者把遺傳變異與生物功能關(guān)聯(lián)起來，從而加大藥物開發(fā)和臨床研究，讓疾病能更早的檢測出來，為患者提供更好的藥物

Illumina China
宜曼達貿(mào)易(上海)有限公司
illumina中國聯(lián)系方式：
上海分公司：
地址：上海市淮海中路333號瑞安廣場2210室
電話：021-61134018
傳真：021-61138320
北京分公司：
地址：北京市朝陽區(qū)曙光西里甲5號鳳凰置地廣場H座1103A室
電話：86-10-8455 4866 
傳真：86-10-8455 4855 

innovative technologies
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina抯 innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
See our corporate overview video 
leading-edge products and services
Illumina has developed a comprehensive line of products that address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine. Our offering includes leading-edge solutions for:
SNP genotyping 
Copy number variation 
DNA methylation studies 
Gene expression profiling 
Low-multiplex analysis of DNA, RNA, and protein
Our products and services are used by a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.
a collaborative approach
In concert with prospective customers and partners, Illumina takes a highly collaborative approach to business relationships. We're good listeners, value feedback, and believe in working together. Illumina is committed to providing our customers with world-class solutions, service, and support throughout their relationship with us to maximize their scientific success.
building the illumina community
Staffed with a cohesive mix of high-performing scientists, engineers, managers, and support staff, Illumina is committed to building a team that delivers high-quality products and industry-leading service to the marketplace. Every employee is a critical part of the growing Illumina Community. Through our actions we strive to invite everyone associated with our company to become a part of this community. This includes customers, collaborators, suppliers, and industry colleagues.
history
Illumina was founded in April of 1998 by David Walt, Ph.D., CW Group (Larry Bock), John Stuelpnagel, D.V.M., Anthony Czarnik, Ph.D., and Mark Chee, Ph.D. While working with CW Group, a venture capital firm, Larry and John uncovered what would become Illumina?s BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Headquartered in San Diego, California, Illumina completed its initial public offering in July, 2000.
Illumina began offering SNP genotyping services in 2001 and launched its first system, the Illumina BeadLab, in 2002, using GoldenGate Genotyping technology. Illumina currently offers microarray-based products and services for an expanding range of genetic analysis sequencing, including SNP genotyping, gene expression, and protein analysis. Illumina?s technologies are used by a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.